Cost–effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C

References

• Akamatsu N, Sugawara Y. Liver transplantation and hepatitis C. Int J Hepatol 2012;2012:686135
   PubMedGoogle Scholar
• EASL Clinical practice guidelines: management of hepatitis C virus infection. J hepatol 2014;60(2):392-420
   PubMed Web of Science ®Google Scholar
• Ramos-Sánchez M del C, Martín-Gil FJ. [Changes in the distribution of hepatitis C virus (HCV) genotypes over the 1999-2010 period in northern Valladolid, Spain]. Rev Esp Salud Publica 2011;85(2):227-30
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Mensa FJ. Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon-free treatment in the SOUND-C2 study. Hepatology 2013;58(4):1516
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405-16
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone JJr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195-206
   PubMed Web of Science ®Google Scholar
• San Miguel R, Gimeno-Ballester V, Blázquez A, Mar J. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 2015;64(8):1277-88
   PubMed Web of Science ®Google Scholar
• Akpo EIH, Cerri K, Kleintjens J. Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis c genotype 1 treatment-naïve patients receiving antiviral therapy. Pharmacoeconomics 2015;33(4):409-22
   PubMed Web of Science ®Google Scholar
• Agencia española de medicamentos y productos sanitarios. Informe de posicionamiento terapéutico de sofosbuvir (Sovaldi®). 2014. Available from: http://aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-sofosbuvir-sovaldi.pdf [Last accessed 25 January 2015]
   Google Scholar
• Tice JA, Ollendorf DA, Chahal HS, et al. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection. 2014. Available from: www.ctaf.org/sites/default/files/assessments/CTAF_Hep_C_Apr14_final. pdf [Last accessed 15 March 2015]
   Google Scholar
• Miller MH, Agarwal K, Austin A, et al. Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther 2014;39(12):1363-75
   PubMed Web of Science ®Google Scholar
• Aronsohn A, Jensen D. Distributive justice and the arrival of direct-acting antivirals: who should be first in line? Hepatology 2011;53(6):1789-91
   PubMed Web of Science ®Google Scholar
• Sociedad española de patología digestiva. The position of the sociedad española de patología digestiva on the current situation of hepatitis C management in Spain. Rev Esp Enferm Dig 2014;106(1):46-50
   PubMedGoogle Scholar
• Siebert U, Alagoz O, Bayoumi M, et al. State-transition modeling: A report of the ISPOR-SMDM modeling good research practices task force-3. Med Decis Making 2012;32:690-700
   PubMed Web of Science ®Google Scholar
• Cock E, Miravitlles M, González-Juanatey JR, Azanza-Perea JR. Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura. Pharmacoeconomics 2007;4(3):97-107
   Google Scholar
• López-Bastida J, Oliva J, Antoñanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 2010;11(5):513-20
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Hezode C, Bronowicki J. Daclatasvir in Combination With Simeprevir ± Ribavirin for Hepatitis C Virus Genotype 1 Infection. In: 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston; Abstract 28LB 2014
   Google Scholar
• Osakidetza: Comité de evaluación de nuevos medicamentos. Informe de evaluación n 20. 2012. Available from: www.osakidetza.euskadi.net/r85-pkcevi03/eu/ [Last accessed 15 March 2015]
   Google Scholar
• Blázquez-Pérez A, San Miguel R, Mar J. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. Pharmacoeconomics 2013;31(10):919-31
   PubMed Web of Science ®Google Scholar
• Buti M, Casado MA, Fosbrook L, Esteban R. [Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha]. Gastroenterol Hepatol 1998;21(4):161-8
   PubMedGoogle Scholar
• Buti M, Casado MA, Fosbrook L, Esteban R. Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1. Pharmacoeconomics 2005;23(10):1043-55
   PubMed Web of Science ®Google Scholar
• San Miguel R, Mar J, Cabasés JM, et al. Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon. Aliment Pharmacol Ther 2003;17(6):765-73
   PubMed Web of Science ®Google Scholar
• Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 2011;14(8):1068-77
   PubMed Web of Science ®Google Scholar
• Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J hepatol 2010;52(5):652-7
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147(10):677-84
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterol 1997;112(2):463-72
   PubMed Web of Science ®Google Scholar
• Planas R, Ballesté B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J hepatol 2004;40(5):823-30
   PubMed Web of Science ®Google Scholar
• Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002;156(8):761-73
   PubMed Web of Science ®Google Scholar
• Registro español de trasplante hepático. Memoria de resultados. Available from: www.ont.es/infesp/Registros/MEMORIARETH2010.pdf
   Google Scholar
• Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127(10):855-65
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Wasem J, et al. Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. Eur J Health Econ 2005;6(2):112-23
   PubMedGoogle Scholar
• Grieve R, Roberts J, Wright M, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006;55(9):1332-8
   PubMed Web of Science ®Google Scholar
• Cure S, Bianic F, Gavart S, et al. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients. J Med Econ 2014;17(1):77-87
   PubMedGoogle Scholar
• Cure S, Bianic F, Gavart S, et al. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. J Med Econ 2014;17(1):65-76
   PubMedGoogle Scholar
• Janssen-Cilag International NV. A study to assess the efficacy and safety of the combination of simeprevir and daclatasvir in chronic hepatitis C genotype 1b- or genotype 4-infected participants - full text view - clinicaltrials.gov. bethesda (MD). Available from: https://clinicaltrials.gov/ct2/show/NCT02268864?term=commit+daclatasvir&rank=1 [Last accessed 15 March 2015]
   Google Scholar
• Janssen R&D Ireland. A study of pharmacokinetics, efficacy, safety, tolerability, of the combination of simeprevir (TMC435), daclatasvir (BMS-790052), and Ribavirin (RBV) in patients with recurrent chronic hepatitis C genotype 1b infection after orthotopic liver transplantation. Bethesda (MD). Available from: https://clinicaltrials.gov/ct2/show/NCT01938625?term=SIMEPREVIR+DACLATASVIR&rank=2 [Last accessed 15 March 2015]
   Google Scholar
• Ministerio de sanidad servicios sociales e igualdad. ministerio de sanidad, servicios sociales e igualdad - gabinete de prensa - notas de prensa. (2015). Available from: www.msssi.gob.es/gabinete/notasPrensa.do?id=3576 [Last accessed 19 April 2015]
   Google Scholar
• Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty: A report of the ISPOR-SMDM modeling good research practices task force-6. Value Health 2012;15:835-42
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMC Med 2013;11:80
   PubMed Web of Science ®Google Scholar
• Chhatwal J, Kanwal F, Roberts MS. Dunn M a. Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States. Ann Intern Med 2015;162:397
   PubMed Web of Science ®Google Scholar
• European medicines agency. Summary of product characteristics: Daklinza. 2014. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf [Last accessed 19 March 2015]
   Google Scholar
• European medicines agency. Summary of product characteristics: Olysio. 2015. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002777/WC500167867.pdf [Last accessed 19 March 2015]
   Google Scholar
• European medicines agency. Summary of product characteristics: Sovaldi. 2015. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf [Last accessed 19 March 2015]
   Google Scholar
• Burgess S, Partovi N, Yoshida EM, et al. A review of drug interactions with direct-acting antivirals for hepatitis C: Implications for HIV and transplant patients. Ann Pharmacother 2015;49(6):674-87
   PubMed Web of Science ®Google Scholar
• Janssen R&D Ireland. An efficacy, safety, tolerability and pharmacokinetics study of 12 weeks treatment with simeprevir and daclatasvir in participants with chronic hepatitis C virus genotype 1b or 4 infection and either severe renal impairment or end-stage renal disease on H. Bethesda (MD): national library of medicine (US). Available from: https://clinicaltrials.gov/ct2/show/NCT02397395?term=simeprevir+daclatasvir&rank=5 [Last accessed 12 April 2015]
   Google Scholar
• Picardo S, Kontorinis N, Tarquinio T, et al. Factors associated with compliance and adherence in the treatment of chronic hepatitis c infection at a tertiary center. J Gastroenterol Hepatol 2014;29:158-9
   Web of Science ®Google Scholar
• Chambers JD, Thorat T, Pyo J, Neumann PJ. The lag from FDA approval to published cost-utility evidence. Expert Rev Pharmacoecon Outcomes Res 2015;15(3):399-402
   PubMed Web of Science ®Google Scholar
• Wonder M. What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry? Expert Rev Pharmacoecon Outcomes Res 2014;14(4):465-7
   PubMed Web of Science ®Google Scholar
• Mar J, Arrospide A, Comas M. Budget impact analysis of thrombolysis for stroke in Spain: a discrete event simulation model. Value Health 2010;13(1):69-76
   PubMed Web of Science ®Google Scholar